VIDEO: Amivantamab plus chemo ‘new standard of care’ in EGFR-mutated NSCLC after progression
Click Here to Manage Email Alerts
MADRID — Amivantamab plus chemotherapy improved PFS, objective response rate and intracranial PFS compared with chemotherapy alone in patients with EGFR-mutated advanced non-small cell lung cancer after progression on osimertinib.
In a video interview with Healio at ESMO Congress, Antonio Passaro, MD, PhD, medical oncologist in the division of thoracic oncology at the European Institute of Oncology in Milan, Italy, discussed the phase 3, global, randomized controlled trial — known as MARIPOSA-2.
“One of the most important results,” according to Passaro, was that adding amivantamab (Rybrevant, Janssen) to standard chemotherapy improved PFS in not only the overall patient population, but also in patients with brain metastases.
“Globally, the results of MARIPOSA-2 confirm that from today we have a new standard-of-care in patients progressing after osimertinib [Tagrisso, AstraZeneca],” Passaro said.
Collapse
Passaro A, et al. Abstract LBA15. Presented at: European Society for Medical Oncology Congress; Oct. 20-24, 2023; Madrid.
Read more about
Click Here to Manage Email Alerts